Goodwin Advises Ardan Equity on its Acquisition of Clinical ink
The Technology M&A and Private Equity teams advised Ardan Equity ("Ardan") on its acquisition of Clinical ink, a global clinical trial technology company, through its flagship Ardan Equity Fund I and affiliated funds.
With Goodwin as counsel, Ardan led the acquisition and recapitalization of Clinical ink, in partnership with GI Partners. Drawing on their complementary life sciences and healthcare technology expertise, Ardan and GI will collaborate closely with management to continue to scale the Clinical ink platform globally, pursue opportunities across clinical research and care, and deliver innovative solutions that meet the rapidly evolving needs of the industry, while maintaining the highest standards of quality and compliance.
Ardan Equity is a private equity firm exclusively focused on the healthcare and life sciences technology sector. Ardan partners collaboratively with founders and management teams to accelerate growth and create differentiated platforms. As founders, operators, and investors, the Ardan team has built many of the defining healthcare and life sciences technology companies across life sciences, payer, provider and employer markets. Ardan utilizes its operator-investor approach and trusted network to help drive risk-adjusted performance. The firm invests capital on behalf of leading institutional investors globally and is headquartered in Palm Beach, Florida.
The Goodwin team was led by John Egan, Larissa Cespedes-Yaffar, Brian Mulhall, Dylan Major, Kahn Wiedis, Kaitlyn Buffaloe, and Nia Saunders (M&A); Eric Willenbacher and Matthew Dunay (Tax), Beth Withers, Jason Yeoun, Katharine Cummings, and Lauren Avery (IP), Ai Tajima, Edward Bota Newton, and Virginia Wong (Risk Management & Insurance), Justin Pierce, Gozde Guckaya, and Kuwabo O’Brien (Global Trade), Andy Barton and Rahat Tariq (Executive Compensation & Benefits), John Goheen, Kevin Walsh, Ortal Ben Aharon, Andrew Jensen, and Elliot Luke (Antitrust), Tim Holahan and Austin Jones (Labor & Employment), Omer Tene and Karl Dragosz (Privacy), Steven Tjoe (Life Sciences Regulatory & Compliance), Anne Brendel (Healthcare), Chris Steinroeder (Debt), and Adam Slutsky (Litigation).
For more information on the deal, please read the press release.